Keryx Biopharmaceuticals to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results
NEW YORK, Feb. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. will hold a conference call on Monday, February 25, 2008 at 8:30 a.m. EST to discuss the fourth quarter and year-end 2007 financial results and business outlook for 2008. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.
In order to participate in the conference call, please call 1-877-874-1565 (U.S.), 1-719-325-4750 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide) oral gelcaps, previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
CONTACT: Lauren Fischer, Director - Investor Relations of Keryx Biopharmaceuticals, Inc., +1-212-531-5965, lfischer@keryx.com
CONTACT: Lauren Fischer, Director - Investor Relations of Keryx
Biopharmaceuticals, Inc., +1-212-531-5965, lfischer@keryx.com
Web site: http://www.keryx.com/